Microorganisms (Jun 2020)

A Multistage Formulation Based on Full-Length CSP and AMA-1 Ectodomain of <i>Plasmodium vivax</i> Induces High Antibody Titers and T-cells and Partially Protects Mice Challenged with a Transgenic <i>Plasmodium berghei</i> Parasite

  • Luciana C. Lima,
  • Rodolfo F. Marques,
  • Alba Marina Gimenez,
  • Katia S. Françoso,
  • Eduardo Aliprandini,
  • Tarsila M. Camargo,
  • Anna Caroline C. Aguiar,
  • Dhelio B. Pereira,
  • Laurent Renia,
  • Rogerio Amino,
  • Irene S. Soares

DOI
https://doi.org/10.3390/microorganisms8060916
Journal volume & issue
Vol. 8, no. 6
p. 916

Abstract

Read online

Infections with Plasmodium vivax are predominant in the Americas, representing 75% of malaria cases. Previously perceived as benign, malaria vivax is, in fact, a highly debilitating and economically important disease. Considering the high complexity of the malaria parasite life cycle, it has been hypothesized that an effective vaccine formulation against Plasmodium should contain multiple antigens expressed in different parasite stages. Based on that, we analyzed a recombinant P. vivax vaccine formulation mixing the apical membrane antigen 1 ectodomain (PvAMA-1) and a full-length circumsporozoite protein (PvCSP-AllFL) previously studied by our group, which elicits a potent antibody response in mice. Genetically distinct strains of mice (C57BL/6 and BALB/c) were immunized with the proteins, alone or in combination, in the presence of poly(I:C) adjuvant, a TLR3 agonist. In C57BL/6, high-antibody titers were induced against PvAMA-1 and the three PvCSP variants (VK210, VK247, and P. vivax-like). Meanwhile, mixing PvAMA-1 with PvCSP-AllFL had no impact on total IgG antibody titers, which were long-lasting. Moreover, antibodies from immunized mice recognized VK210 sporozoites and blood-stage parasites by immunofluorescence assay. However, in the BALB/c model, the antibody response against PvCSP-AllFL was relatively low. PvAMA-1-specific CD3+CD4+ and CD3+CD8+ T-cell responses were observed in C57BL/6 mice, and the cellular response was impaired by PvCSP-AllFL combination. More relevant, the multistage vaccine formulation provided partial protection in mice challenged with a transgenic Plasmodium berghei sporozoite expressing the homologous PvCSP protein.

Keywords